Pfizer Inc. (NYSE:PFE) Shares Sold by Strategic Blueprint LLC

Strategic Blueprint LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 11.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,227 shares of the biopharmaceutical company’s stock after selling 6,162 shares during the period. Strategic Blueprint LLC’s holdings in Pfizer were worth $1,338,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Diversify Advisory Services LLC raised its holdings in shares of Pfizer by 3.7% during the 3rd quarter. Diversify Advisory Services LLC now owns 406,186 shares of the biopharmaceutical company’s stock valued at $11,714,000 after buying an additional 14,457 shares during the period. Integrated Advisors Network LLC grew its position in Pfizer by 18.3% in the third quarter. Integrated Advisors Network LLC now owns 64,014 shares of the biopharmaceutical company’s stock valued at $1,853,000 after acquiring an additional 9,925 shares in the last quarter. Fortitude Family Office LLC grew its position in Pfizer by 39.7% in the third quarter. Fortitude Family Office LLC now owns 13,763 shares of the biopharmaceutical company’s stock valued at $398,000 after acquiring an additional 3,914 shares in the last quarter. Wells Trecaso Financial Group LLC lifted its position in shares of Pfizer by 2.5% during the third quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company’s stock worth $416,000 after purchasing an additional 350 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Pfizer by 132.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 20,361 shares of the biopharmaceutical company’s stock valued at $589,000 after purchasing an additional 11,615 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on PFE. UBS Group boosted their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Price Performance

Shares of NYSE:PFE opened at $28.47 on Wednesday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm has a 50-day simple moving average of $29.07 and a 200 day simple moving average of $28.56. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The company has a market cap of $161.33 billion, a PE ratio of -61.89, a P/E/G ratio of 0.99 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the prior year, the firm earned $0.67 EPS. The business’s quarterly revenue was up 2.1% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.90%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is presently -365.21%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.